The relationship between paraoxonase-1 activity and coronary artery disease in patients with metabolic syndrome

Turk Kardiyoloji Dernegi Arsivi

Volumn 39, Issue 5, 2011, Pages 371-377

  Akçay, Adnan Burak ^a,b   Çamsari, Ahmet ^a   Özcan, Türkay ^a   Çiçek, Dilek ^a   Akkuş, Necdet ^a   Seyis, Sabri ^a   Çimen, Burak ^a   Çelebi, Bariş ^a   Döven, Oben ^a   Cin, Gökhan ^a  

^a MERSIN UNIVERSITY   (Turkey)

^b MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

Angina pectoris; Aryldialkylphosphatase blood; Coronary artery disease; Metabolic syndrome X

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; INSULIN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER;

ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENSINI SCORE; GROUPS BY AGE; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; SCORING SYSTEM; STABLE ANGINA PECTORIS; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PREDICTIVE VALUE;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84555188314     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2011.01382     Document Type: Article

References (24)

1. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-9.
2. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507. (Pubitemid 26159866)
3. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83. (Pubitemid 20151285)
4. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76. (Pubitemid 26167018)
5. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-5. (Pubitemid 29072747)
6. Kabaroǧlu C, Mutaf İ, Boydak B, Özmen D, Habif S, Erdener D, et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol 2004;59:606-11. (Pubitemid 39619965)
7. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003;88:5422-6. (Pubitemid 37452748)
8. Peppes V, Rammos G, Manios E, Koroboki E, Rokas S, Zakopoulos N. Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: a hospital-based, prospective study in Greek patients. Clin Interv Aging 2008;3:699-710.
9. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
10. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001;131:2082-9. (Pubitemid 32720634)
11. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999;147:405-10. (Pubitemid 29512273)
12. Chandra M, Chandra N, Agrawal R, Kumar A, Ghatak A, Pandey VC. The free radical system in ischemic heart disease. Int J Cardiol 1994;43:121-5. (Pubitemid 24073669)
13. Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioǧlu E, Altintaş N, et al. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. [Article in Turkish] Türk Kardiyol Dern Arş 2009;37:473-8.
14. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 2002;28:297-304.
15. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002;32:259-64. (Pubitemid 36216591)
16. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7. (Pubitemid 34219807)
17. Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2264-9. (Pubitemid 40586272)
18. Yilmaz H, Sayar N, Yilmaz M, Gürkan U, Sesal C, Tosu R, et al. Serum paraoxonase 1 activity in women with metabolic syndrome. Kardiol Pol 2010;68:1219-24.
19. Tabur S, Torun AN, Sabuncu T, Turan MN, Çelik H, Ocak AR, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol 2010;162:535-41.
20. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-50. (Pubitemid 44288981)
21. Gür M, Aslan M, Yildiz A, Demirbaǧ R, Yilmaz R, Selek S, et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006;36:779-87. (Pubitemid 44569966)
22. Granér M, James RW, Kahri J, Nieminen MS, Syvänne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006;47:2429-35. (Pubitemid 43866362)
23. Sözmen B, Delen Y, Girgin FK, Sözmen EY. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clin Biochem 1999;32:423-7. (Pubitemid 29536174)
24. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991;40:277-82.